Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma

Overview of attention for article published in Frontiers in immunology, January 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 5 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 50,890 followers.

Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma https://t.co/yFnwkmDYUi https://t.co/iCIo3KluRi

22 Jan 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a pati…

21 Jan 2023

Reply Repost Favourite

New Research: Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma: Anti-PD-1 immunotherapy has been extensively used in treatment of… https://t.co/Li1b

21 Jan 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.